Cytomegalovirus Infection and Alzheimer’s Disease: A Meta-Analysis - 21/11/24
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Background |
Evidence on the association of cytomegalovirus (CMV) infection with Alzheimer’s disease (AD) is scarce and the results are inconsistent.
Objective |
To investigate the association of CMV infection with the risk of AD.
Methods |
Observational studies on the relationship between CMV infection and AD were identified from PubMed, Embase, Web of Science, and the Cochrane Library until September 30, 2022. The quality of included studies was assessed using the Newcastle-Ottawa Scale. Random-effect meta-analysis was performed using a generic inverse-variance method, followed by sensitivity analyses and subgroup analyses based on study designs, regions, adjustments, and population types.
Results |
Our search yielded 870 articles, of which 200 were duplicates and 663 did not meet the inclusion criteria, and finally yielded seven studies with 6,772 participants. No strong evidence was observed in the summary analysis for the association of CMV infection and risk of AD (odds ratio [OR] = 1.33; 95% confidence interval [CI]: 0.88, 2.03, I2 =69.9%). However, subgroup analysis showed that an increased risk of AD was detected in East Asians (OR = 2.39; 95% CI: 1.63, 3.50, I2 = 0.00%), cohort studies (OR = 1.99; 95% CI: 1.35, 2.94, I2 = 28.20%), and studies with confounder adjustment (OR = 2.05; 95% CI: 1.52, 2.77, I2 = 0.00%).
Conclusions |
This meta-analysis provides evidence to support the heterogeneity of the associations between CMV infection and AD. Future studies with larger sample sizes and multi-ethnic populations are necessary.
Il testo completo di questo articolo è disponibile in PDF.Key words : Cytomegalovirus infections, human herpesvirus, Alzheimer’s disease, meta-analysis
Mappa
| How to cite this article: Q. Ji, W. Lian, Y. Meng, et al. Cytomegalovirus Infection and Alzheimer’s Disease: A Meta-Analysis. J Prev Alz Dis 2023; jpad.2023.126 |
Vol 11 - N° 2
P. 422-427 - Marzo 2024 Ritorno al numero
Articolo precedente
- Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer’s Disease
- A.C. Macedo, D.F.P.A. Durço, C. Tissot, J. Therriault, A.O. Vilela de Faria, É. Aumont, S. Servaes, N. Rahmouni, J. Fernandez-Arias, Y.-T. Wang, F.Z. Lussier, A. Bieger, E.R. Zimmer, T.A. Pascoal, S. Gauthier, Pedro Rosa-Neto
- Nanolithium, a New Treatment Approach to Alzheimer’s Disease: A Review of Existing Evidence and Clinical Perspectives
- Solene Guilliot, E.N. Wilson, J. Touchon, M.E. Soto
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.